RTW Investments, LP disclosed a 9.99% passive ownership stake in Tenax Therapeutics in an SEC filing on August 14, 2026. The firm reported beneficial ownership of 2,866,654 common shares. This figure includes shares issuable upon the exercise of warrants. The disclosure is based on 26,525,159 shares outstanding as of May 8, 2026.
The investment follows a nearly 90% collapse in Tenax’s stock price on August 10, 2026. This sell-off occurred after the company’s Phase 3 LEVEL clinical trial for TNX-103 failed to meet its primary endpoint.
RTW Investments is a specialized life sciences investor. The passive designation indicates the firm does not currently intend to influence or control the company.